Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 Monoclonal antibodies for relapsing-remitting multiple sclerosis (RRMS)

From: Recent developments in multiple sclerosis therapeutics

Agent

Proposed mechanisms of action

Stage of development*

Alemtuzamab

Leukocyte depletion; Depletes CD52 B and T cell populations, monocytes, macrophages and eosinophils

Phase III for RRMS

Daclizumab

Leukocyte depletion; Binds cell-surface receptor IL2; reduces T cell proliferation and activation

Phase II for RRMS

Rituximab

B cell-directed therapy; Depletes CD20 B cell population

Phase III for RRMS

  1. *Compiled from http://www.clinicaltrials.gov
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us